Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Nelson L. Michael, Jason Thompson et al.|The Lancet|2017Cited by 196
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Stephen J. Thomas, Michael Koren et al.|The Journal of Infectious Diseases|2020Cited by 24
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael Koren, Kayvon Modjarrad, Leyi Lin et al.|The Lancet Infectious Diseases|2023Cited by 23
Pre-existing Immunity to Japanese Encephalitis Virus Alters CD4 T Cell Responses to Zika Virus Inactivated VaccineNoemia S. Lima, Lydie Trautmann, Damee Moon et al.|Frontiers in Immunology|2021Cited by 19
Safety and Immunogenicity of an AS03B-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Alexander C. Schmidt, Kirsten E. Lyke et al.|American Journal of Tropical Medicine and Hygiene|2020Cited by 17